Pure Biologics Spólka Akcyjna (PUR) - Total Liabilities

Latest as of September 2025: zł20.72 Million PLN ≈ $5.70 Million USD

Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has total liabilities worth zł20.72 Million PLN (≈ $5.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Pure Biologics Spólka Akcyjna (PUR) equity growth momentum to track the company's year-over-year net asset growth rate.

Pure Biologics Spólka Akcyjna - Total Liabilities Trend (2016–2024)

This chart illustrates how Pure Biologics Spólka Akcyjna's total liabilities have evolved over time, based on quarterly financial data. See PUR FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Pure Biologics Spólka Akcyjna Competitors by Total Liabilities

The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their total liabilities.

Company	Country	Total Liabilities
Winfarm PA:ALWF	France	€57.66 Million
Paratech Company Limited KQ:033540	Korea	₩110.79 Billion
Quoin Pharmaceuticals Ltd DRC NASDAQ:QNRX	USA	$6.92 Million
Indo Straits Tbk JK:PTIS	Indonesia	Rp11.01 Million
Harper Hygienics S.A. WAR:HRP	Poland	zł180.43 Million
Cambium Networks Corp NASDAQ:CMBM	USA	$177.06 Million
Batero Gold Corp V:BAT	Canada	CA$2.49 Million
Umpas Holding AS IS:UMPAS	Turkey	TL211.88 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Pure Biologics Spólka Akcyjna's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PUR company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	15.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pure Biologics Spólka Akcyjna's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pure Biologics Spólka Akcyjna (2016–2024)

The table below shows the annual total liabilities of Pure Biologics Spólka Akcyjna from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	zł15.46 Million ≈ $4.25 Million	-25.84%
2023-12-31	zł20.84 Million ≈ $5.74 Million	+41.69%
2022-12-31	zł14.71 Million ≈ $4.05 Million	+90.97%
2021-12-31	zł7.70 Million ≈ $2.12 Million	-64.71%
2020-12-31	zł21.83 Million ≈ $6.01 Million	+49.80%
2019-12-31	zł14.57 Million ≈ $4.01 Million	+234.41%
2018-12-31	zł4.36 Million ≈ $1.20 Million	+290.25%
2017-12-31	zł1.12 Million ≈ $307.30K	+74.43%
2016-12-31	zł640.12K ≈ $176.17K	--

About Pure Biologics Spólka Akcyjna

WAR:PUR Poland Biotechnology

Market Cap

$8.76 Million

zł31.84 Million PLN

Market Cap Rank

#27386 Global

#297 in Poland

Share Price

zł2.81

Change (1 day)

+26.01%

52-Week Range

zł1.42 - zł7.70

All Time High

zł142.00